The Effectiveness of Risankizumab as Induction Therapy for Crohn’s Disease: Data From the Sicilian Network for Inflammatory Bowel Diseases
Lay Summary This multicentre cohort study showed that Risankizumab is an effective induction therapy in patients with Crohn’s disease, and that the best results are obtained when Risankizumab is used as second-line therapy following a previous failure with a TNF inhibitor.
Authors
- Luca Bertoncello
- Filippo Mocciaro (ORCID: https://orcid.org/0000-0002-4389-0643)
- Ambrogio Orlando (ORCID: https://orcid.org/0000-0002-5298-2638)
- Walter Fries (ORCID: https://orcid.org/0000-0001-6159-7478)
- Sara Renna (ORCID: https://orcid.org/0000-0001-8270-2978)
- B. Scrivo (ORCID: https://orcid.org/0000-0002-0329-9488)
- A Termini
- Fabio Salvatore Macaluso (ORCID: https://orcid.org/0000-0001-5128-3846)
- Maria Emanuela Distefano
- Vincenza Tortorella
- Concetta Ferracane
- Emiliano Giangreco
- Anna Viola (ORCID: https://orcid.org/0000-0002-1733-6489)
- Maria Giovanna Minissale
- Maria Cappello
- I A Salerno
Institutions
- Ospedale Vincenzo Cervello (IT)
- Hospital Universitario Araba (ES)
- Ospedale Cannizzaro (IT)
- University of Palermo (AR)
- Azienda Ospedaliera Universitaria Policlinico "G. Martino" (IT)
- Azienda Ospedaliero Universitaria Policlinico "G.Rodolico - San Marco" (IT)
- Ospedale Buccheri la Ferla Fatebenefratelli (IT)
- Azienda Ospedaliera Ospedali Riuniti Papardo Piemonte (IT)
Publication Details
- Journal
- Inflammatory Bowel Diseases
- Published
- 2024-10-26
- DOI
- https://doi.org/10.1093/ibd/izae248
- Citations
- 2
- Primary Topic
- Inflammatory Bowel Disease
- Type
- article
- Field-Weighted Citation Impact
- 1.10